The possible benefit deriving from an induction treatment with targeted therapy with BRAF + MEK inhibitors (encorafenib and binimetinib) prior to combined immunotherapy with nivolumab plus ipilimumab in patients with advanced BRAFV600-mutant melanoma was explored in the EORTC phase II randomized EBIN study [118]. Here, BRAF is linked to melanoma.